Speciality Medicines IPO Listing at 4.4% Premium at ₹129.50 Per Share

Mon Mar 30 2026

Speciality Medicines IPO Listing Today: The Speciality Medicines IPO was subscribed 0.22 times as of its closing. In this subscription, qualified institutional buyers (QIBs) received 0.00 times, and non-institutional investors (NIIs) received 0.11 times. The retail quota of the issue was subscribed to 49.55%. Before delving deeper into the topic, go through the details of the Speciality Medicines IPO.

Table of Contents

Speciality Medicines IPO

It is a bookbuilding issue IPO of ₹29.14 crore, entirely an fresh issue of 0.24 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 30th March 2026. The Speciality Medicines IPO date is scheduled from 20th March 2026 to 24th March 2026. The face value of Speciality Medicines shares stands at ₹10 per share, and the IPO Issue price band is set at ₹117 to ₹124 per share.

Speciality Medicines IPO Details

IPO Allotment Date	25th March 2026
IPO Open Date	20th March 2026
IPO Close Date	24th March 2026
Refund Initiation	27th March 2026
Issue Size	23,50,000 shares(agg. up to ₹29 Cr
Face Value	₹10 per share
Lot Size	1,000 shares
Issue Price	₹117 to ₹124 per share
Issue Type	Bookbuilding IPO
Listing At	BSE & SME
Listing Date	30th March 2026

Speciality Medicines IPO Listing

On the BSE & SME platforms, Speciality Medicines shares are listed at ₹129.50 per share, reflecting a 4.4% premium over the issue price of ₹124 per share.

About Speciality Medicines Limited

Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals—including high-cost oral and injectable medications used to treat complex chronic conditions—across both domestic and international markets. The company’s portfolio includes a wide range of specialty pharmaceutical finished formulations, available in various dosage forms, including tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.

Speciality Medicines Limited Financials

The company’s financial analysis is essential before applying for the Speciality Medicines IPO. See the table for Speciality Medicines Limited’s financials.

Year Ended	31st Dec 2025 (in cr.)	31st March 2025 (in cr.)	31st March 2024 (in cr.)
Assets	45.57	39.98	22.68
Total Income	36.63	58.54	27.66
Profit After Tax	6.06	8.61	2.93
EBITDA	6.51	9.09	5.26
Net Worth	36.47	30.42	15.06
Reserves and Surplus	30.04	23.98	9.95
Total Borrowings	4.81	5.05	2.86

Explanation

Speciality Medicines Limited’s revenue increased by 23.01%, from ₹58.54 crore in March 2024 to ₹36.93 crore in March 2025. Moreover, the company’s PAT increased by 32.52% from ₹8.61 crore in March 2024 to ₹6.06 crore in March 2025.